Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875801 | 0.91 | DGKA (0.52) | NAAADGKAHTR2CPTGS2CA12 | |
| SCHEMBL14697023 | 0.89 | CA12 (0.46) | NAAADGKAHTR2CPTGS2CA12 | |
| SCHEMBL29293359 | 0.88 | DGKA (0.47) | NAAADGKAHTR2CPTGS2CA12 | |
| SCHEMBL9951891 | 0.86 | DGKA (0.59) | NAAADGKAHTR2CALDH1A1TDP1 | |
| SCHEMBL10063280 | 0.85 | CA12 (0.44) | DGKAPTGS2CA12CA1CA2 | |
| SCHEMBL23036025 | 0.85 | CA12 (0.43) | DGKAHTR2CPTGS2CA12CA1 | |
| SCHEMBL22615111 | 0.85 | DGKA (0.62) | NAAADGKAHTR2CALDH1A1TDP1 | |
| SCHEMBL22615105 | 0.85 | DGKA (0.62) | NAAADGKAHTR2CALDH1A1TDP1 | |
| SCHEMBL22615113 | 0.85 | DGKA (0.62) | NAAADGKAHTR2CALDH1A1TDP1 | |
| SCHEMBL421653 | 0.82 | NAAA (0.60) | NAAADGKAHTR2CALDH1A1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137599-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE | NICOX S.A. (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2170803-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONONITRATE | Nicox S.A. (FR) | 2010-04-07 | — | — | EP | claimed |
| WO-2009000723-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONONITRATE | NICOX S.A. (FR) | 2008-12-31 | — | — | WO | claimed |
| EP-3021870-B1 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE DONOR | NICOX SCIENCE IRELAND LTD (IE) | 2018-02-21 | — | — | EP | disclosed |
| US-9895335-B2 | Ophthalmic compositions containing a nitric oxide donor | NICOX SCIENCE IRELAND (IE) | 2018-02-20 | — | — | US | disclosed |
| US-20160158182-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE DONOR | NICOX SA (FR) | 2016-06-09 | — | — | US | disclosed |
| EP-3021870-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE DONOR | Nicox Science Ireland (IE) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007552-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE DONOR | NICOX SCIENCE IRELAND (IE) | 2015-01-22 | — | — | WO | disclosed |
| EP-2826491-A1 | Ophthalmic compositions containing a nitric oxide donor | Nicox Science Ireland (IE) | 2015-01-21 | — | — | EP | disclosed |
| US-20100137599-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE | NICOX S.A. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2170803-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONONITRATE | Nicox S.A. (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009000723-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONONITRATE | NICOX S.A. (FR) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137599-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE | CYP11B1, CYP11B2, HSD17B7 | NAAA 2575/4885DGKA 2881/4885HTR2C 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.